Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		RTOG0627 Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme

		Phase:		Phase 2

		Treatment ID#:		1797 RTOG 06-27

		Age Group:		Adult And Pediatric

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed

		Last Updated:		04/13/2010

		Tumor Types:		Glioblastoma Multiforme Low Grade Glioma


		Comments:		The use of single agents that target multiple molecular abnormalities driving glioma growth may improve outcome. Dasatinib is such an agent. Dasatinib (BMS-354825) is an orally administered protein tyrosine kinase (PTK) inhibitor with specificity for five kinases/kinase families that have been strongly linked to multiple forms of human malignancies. These targets include: BCR-ABL, c-SRC, c- KIT, PDGFâ receptor, and EPHA2.

		Treatment Type:		Immunological, Biological or Targeted Therapy

		Contact:		Clinical Trials Office - Akron City Hospital Akron City Hospital Akron, OH 44309 USA Phone: 330-375-6101 Fax: E-mail: Website:

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2010 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By